Product Information
GABAPENTIN 300 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.0314 per EA under NDC 00480349505. Its NADAC has been published 32 times since Feb 25, 2026.
FDA first approved this application on Sep 12, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480349505
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA075350FDA Approved
9/12/2003
TE Code
AB
On Market Since
1/12/2026
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 300 MG CAPSULE has been published 32 times since Feb 25, 2026, and over the history we have for it it has declined 6.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0314 per EA |
|---|---|
| All-time high | $0.0334 (Mar 11, 2026) |
| All-time low | $0.0301 (Aug 19, 2026) |
| 52-week high | $0.0334 |
| 52-week low | $0.0301 |
| Median price | $0.0325 |
| Average price | $0.0320 |
| Largest weekly change | -5.1% (Jul 22, 2026) |
| Weeks tracked | 32 |
| Tracking since | Feb 25, 2026 |
Generic Alternatives
The matcher finds 16 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 300 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.0314 per EA (NDC 00480349505), effective Sep 30, 2026.
How has the price of GABAPENTIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 300 MG CAPSULE has declined 6.0%. It has been tracked across 32 weekly CMS publications since Feb 25, 2026.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 300 MG CAPSULE?
Since Feb 25, 2026, the NADAC for GABAPENTIN 300 MG CAPSULE has ranged from a low of $0.0301 (Aug 19, 2026) to a high of $0.0334 (Mar 11, 2026), with a median of $0.0325 per EA.
Are there cheaper alternatives to GABAPENTIN 300 MG CAPSULE?
Yes. 16 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 300 MG CAPSULE, is $0.0301 per EA — about 4% below GABAPENTIN 300 MG CAPSULE.
Who manufactures GABAPENTIN 300 MG CAPSULE?
GABAPENTIN 300 MG CAPSULE (NDC 00480349505) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.